- Home
- ARDX vs CHI Comparison
ARDX vs CHI Comparison
Compare ARDX & CHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDX
- CHI
- Stock Information
- Founded
- ARDX 2007
- CHI 2002
- Country
- ARDX United States
- CHI United States
- Employees
- ARDX N/A
- CHI N/A
- Industry
- ARDX Biotechnology: Pharmaceutical Preparations
- CHI Investment Managers
- Sector
- ARDX Health Care
- CHI Finance
- Exchange
- ARDX Nasdaq
- CHI Nasdaq
- Market Cap
- ARDX 882.9M
- CHI 840.2M
- IPO Year
- ARDX 2014
- CHI N/A
- Fundamental
- Price
- ARDX $5.13
- CHI $11.05
- Analyst Decision
- ARDX Strong Buy
- CHI
- Analyst Count
- ARDX 9
- CHI 0
- Target Price
- ARDX $10.50
- CHI N/A
- AVG Volume (30 Days)
- ARDX 3.0M
- CHI 186.2K
- Earning Date
- ARDX 10-30-2025
- CHI 01-01-0001
- Dividend Yield
- ARDX N/A
- CHI 9.90%
- EPS Growth
- ARDX N/A
- CHI N/A
- EPS
- ARDX N/A
- CHI N/A
- Revenue
- ARDX $386,146,000.00
- CHI N/A
- Revenue This Year
- ARDX $17.34
- CHI N/A
- Revenue Next Year
- ARDX $27.08
- CHI N/A
- P/E Ratio
- ARDX N/A
- CHI N/A
- Revenue Growth
- ARDX 83.88
- CHI N/A
- 52 Week Low
- ARDX $3.21
- CHI $9.70
- 52 Week High
- ARDX $6.84
- CHI $11.61
- Technical
- Relative Strength Index (RSI)
- ARDX 28.38
- CHI 68.65
- Support Level
- ARDX $5.24
- CHI $10.58
- Resistance Level
- ARDX $6.78
- CHI $11.00
- Average True Range (ATR)
- ARDX 0.20
- CHI 0.14
- MACD
- ARDX -0.15
- CHI 0.01
- Stochastic Oscillator
- ARDX 3.01
- CHI 90.91
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.